ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cemiplimab

Also written as “Cemiplimab”, “REGN2810” and “REGN2810/chemo/ipi”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Basal Cell · Squamous Cell Carcinoma of Head and Neck · Neoplasm Metastasis, led by 7 companies.

Drug pageCemiplimab: every studyMany companies study it; this page follows only the 42 they lead. All 135 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Mar 3, 201742 company-led studies, 18 open or runningNext primary completion: Mar 22, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals3516 open or runningphase 3since Mar 3, 2017Feb 2, 2015Mar 22, 2027phase 3 · NCT06246916
BioNTechits history only20 open or runningphase 2since Apr 21, 2020Apr 21, 2020none ahead
Maia Biotechnologyits history only11 open or runningphase 3since Mar 20, 2025Mar 20, 2025Jul 31, 2027phase 3 · NCT06908304
Merck KGaA, Darmstadt, Germanyits history only10 open or runningphase 2since May 22, 2023May 22, 2023none ahead
Sanofiits history only10 open or runningphase 2since Jun 19, 2017Jun 19, 2017none ahead
SillaJenits history only10 open or runningphase 2since Sep 19, 2017Sep 19, 2017none ahead
Vyriadits history only11 open or runningphase 2since Feb 25, 2020Feb 25, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Regeneron Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 22 earlier studies, Feb 2, 2015 to Apr 15, 2020.

  1. Jun 9, 2018Named cemiplimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, REGN2810
  2. Nov 6, 2020Phase 2 study in Advanced Solid TumorsNCT04626635 · 548 enrolled · United States, France, Israel and more
  3. Jan 24, 2022Phase 1 study in Neoplasm MetastasisNCT05259709 · 22 enrolled · Netherlands
  4. Sep 23, 2022Phase 2 study in Advanced Non-Small Cell Lung CancerNCT05557591 · 51 enrolled · United States, Georgia, Germany and more
  5. Nov 9, 2023Phase 2 study in MelanomaNCT06190951 · 151 enrolled · United States, Australia, Austria and more
  6. Jan 30, 2024Phase 3 study in MelanomaNCT06246916 · 560 planned · United States, Canada
  7. Apr 22, 2024Phase 2 study in Cutaneous Squamous Cell CarcinomaNCT06384820
  8. May 9, 2024Phase 2 study in MelanomaNCT06413680 · 240 planned · United States
  9. Jun 6, 2024Phase 1 study in Carcinoma, Ovarian EpithelialNCT06469281 · 90 planned · United States
  10. Sep 3, 2024Phase 3 study in Skin NeoplasmsNCT06585410 · 369 planned · United States, Australia
  11. Jan 6, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06769698 · 120 planned · United States, Australia, France and more
  12. Feb 24, 2025Phase 2 study in MelanomaNCT06848088 · 28 enrolled · United States, Ireland
  13. Apr 28, 2026Phase 2 study in GliomaNCT07567469 · 120 planned
  14. Sep 1, 2026Phase 2 study in Skin NeoplasmsNCT07808515 · 135 planned
  15. Nov 10, 2026Primary completion moved from 2029-10-10 to 2030-10-09Date moved laterphase 2 · +12 months · NCT06848088

Ahead

  1. Nov 2, 2026Primary completion: phase 2 study in MelanomaNCT06190951
  2. Nov 13, 2026Primary completion: phase 2 study in Advanced Solid TumorsNCT04626635
  3. Mar 22, 2027Primary completion: phase 3 study in MelanomaNCT06246916
  4. Apr 29, 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT05259709

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 35 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07808515Skin Neoplasms2Not yet recruitingNov 13, 2030135
NCT07567469Glioma2Not yet recruitingAug 27, 2032120
NCT06848088Melanoma · United States, Ireland2Active, not recruitingOct 9, 203028
NCT06769698Squamous Cell Carcinoma of Head and Neck · United States, Australia, France and more2RecruitingJun 4, 2028120
NCT06585410Skin Neoplasms · United States, Australia3RecruitingMay 3, 2030369
NCT06469281Carcinoma, Ovarian Epithelial · United States1RecruitingMay 27, 203090
NCT06413680Melanoma · United States2RecruitingFeb 3, 2030240
NCT06384820Cutaneous Squamous Cell Carcinoma2WithdrawnJun 8, 20260
NCT06246916Melanoma · United States, Canada3RecruitingMar 22, 2027560
NCT06190951Melanoma · United States, Australia, Austria and more2Active, not recruitingNov 2, 2026151
NCT05557591Advanced Non-Small Cell Lung Cancer · United States, Georgia, Germany and more2Active, not recruitingJan 26, 202851
NCT05259709Neoplasm Metastasis · Netherlands1Active, not recruitingApr 29, 202722
NCT04626635Advanced Solid Tumors · United States, France, Israel and more2Active, not recruitingNov 13, 2026548
NCT04373083Hodgkin Disease2WithdrawnDec 20, 20220
NCT04154943Cutaneous Squamous Cell Carcinoma · United States, Australia, Germany2CompletedDec 1, 202179
NCT03969004Cutaneous Squamous Cell Carcinoma · United States, Australia, Belgium and more3Active, not recruitingJan 7, 2028415
NCT03916627Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingMar 31, 202565
NCT03889912Carcinoma, Basal Cell · United States, Australia, Netherlands1CompletedNov 13, 202597
NCT03690869Central Nervous System Neoplasms · United States2TerminatedMay 10, 202357
NCT03580694Carcinoma, Non-Small-Cell Lung · United States1TerminatedDec 4, 201917
NCT03564340Ovarian Neoplasms · United States, Australia, Belgium and more2RecruitingMay 10, 2027890
NCT03515629Carcinoma, Non-Small-Cell Lung · United States, Italy, Lithuania3TerminatedJul 29, 20215
NCT03430063Advanced Non-Small Cell Lung Carcinoma · United States, Belgium, France and more2TerminatedOct 27, 202128
NCT03409614Carcinoma, Non-Small-Cell Lung · United States, Austria, China and more3CompletedFeb 27, 2025789
NCT03257267Carcinoma, Squamous Cell · United States, Australia, Belgium and more3CompletedMar 15, 2021608
NCT03233139Advanced Malignancies · Japan1Active, not recruitingSep 30, 2027146
NCT03198130Recurrent Squamous Cell Carcinoma of Head · Korea, Republic of, United Kingdom1CompletedJun 27, 201933
NCT03132636Carcinoma, Basal Cell · United States, Austria, Belgium and more2CompletedMay 20, 2021138
NCT03088540Carcinoma, Non-Small-Cell Lung · Australia, Belarus, Brazil and more3CompletedApr 18, 2025712
NCT03002376Melanoma · Korea, Republic of, Netherlands, Serbia and more1CompletedMar 5, 201947
NCT03005782Neoplasms · United States, Australia, Ireland and more1CompletedApr 2, 2024333
NCT02760498Advanced Cutaneous Squamous Cell Carcinoma · United States, Australia, Brazil and more2CompletedOct 18, 2023432
NCT02651662Recurrence · United States, Austria, Germany and more1CompletedApr 29, 2026105
NCT02520245Advanced Malignancies · United States1WithdrawnNov 20230
NCT02383212Advanced Cancer · United States, Australia, Spain1CompletedNov 18, 2019398

How it is read

Names in the registry

  • “Cemiplimab”, 23 entries
  • “cemiplimab”, 9 entries
  • “REGN2810”, 4 entries
  • “REGN2810/chemo/ipi”, 2 entries
  • “Fianlimab+cemiplimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.